Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 128

1.

Surfactant Protein D Deficiency Aggravates Cigarette Smoke-Induced Lung Inflammation by Upregulation of Ceramide Synthesis.

Pilecki B, Wulf-Johansson H, Støttrup C, Jørgensen PT, Djiadeu P, Nexøe AB, Schlosser A, Hansen SWK, Madsen J, Clark HW, Nielsen CH, Vestbo J, Palaniyar N, Holmskov U, Sorensen GL.

Front Immunol. 2018 Dec 18;9:3013. doi: 10.3389/fimmu.2018.03013. eCollection 2018.

2.

Increased surfactant protein-D levels in the airways of preterm neonates with sepsis indicated responses to infectious challenges.

Mackay RA, Townsend JP, Calvert J, Anthony M, Wilkinson AR, Postle AD, Clark HW, Todd DA.

Acta Paediatr. 2019 May;108(5):870-876. doi: 10.1111/apa.14630. Epub 2019 Jan 8.

3.

Surfactant Proteins A and D: Trimerized Innate Immunity Proteins with an Affinity for Viral Fusion Proteins.

Watson A, Phipps MJS, Clark HW, Skylaris CK, Madsen J.

J Innate Immun. 2019;11(1):13-28. doi: 10.1159/000492974. Epub 2018 Oct 5. Review.

4.

Metabolism of a synthetic compared with a natural therapeutic pulmonary surfactant in adult mice.

Madsen J, Panchal MH, Mackay RA, Echaide M, Koster G, Aquino G, Pelizzi N, Perez-Gil J, Salomone F, Clark HW, Postle AD.

J Lipid Res. 2018 Oct;59(10):1880-1892. doi: 10.1194/jlr.M085431. Epub 2018 Aug 14.

5.

Structural definition of hSP-D recognition of Salmonella enterica LPS inner core oligosaccharides reveals alternative binding modes for the same LPS.

Littlejohn JR, da Silva RF, Neale WA, Smallcombe CC, Clark HW, Mackay RA, Watson AS, Madsen J, Hood DW, Burns I, Greenhough TJ, Shrive AK.

PLoS One. 2018 Jun 18;13(6):e0199175. doi: 10.1371/journal.pone.0199175. eCollection 2018.

6.

Marijuana Initiatives Versus Legislation and Public Health.

Clark HW.

Am J Public Health. 2018 Jul;108(7):854-856. doi: 10.2105/AJPH.2018.304456. No abstract available.

PMID:
29874520
7.

Successfully implementing and embedding guidelines to improve the nutrition and growth of preterm infants in neonatal intensive care: a prospective interventional study.

Johnson MJ, Leaf AA, Pearson F, Clark HW, Dimitrov BD, Pope C, May CR.

BMJ Open. 2017 Dec 6;7(12):e017727. doi: 10.1136/bmjopen-2017-017727.

8.

The Physicians' Case for Marijuana Legalization.

Nathan DL, Clark HW, Elders J.

Am J Public Health. 2017 Nov;107(11):1746-1747. doi: 10.2105/AJPH.2017.304052. No abstract available.

9.

Health Reform and the Substance Use Disorder Treatment System: A Time of Change.

Clark HW.

J Psychoactive Drugs. 2017 Apr-Jun;49(2):91-94. doi: 10.1080/02791072.2017.1315471. No abstract available.

PMID:
28574802
10.

Non-Pulmonary Immune Functions of Surfactant Proteins A and D.

Ujma S, Horsnell WG, Katz AA, Clark HW, Schäfer G.

J Innate Immun. 2017;9(1):3-11. doi: 10.1159/000451026. Epub 2016 Oct 29. Review.

11.

Advancing smoke-free policy adoption on the Navajo Nation.

Nez Henderson P, Roeseler A, Moor G, Clark HW, Yazzie A, Nez P, Nez C, Sabo S, Leischow SJ.

Tob Control. 2016 Oct;25(Suppl 1):i26-i31. doi: 10.1136/tobaccocontrol-2016-053109.

12.

Response.

Mackay RM, Grainge CL, Lau LC, Barber C, Clark HW, Howarth PH.

Chest. 2016 Aug;150(2):474. doi: 10.1016/j.chest.2016.05.033. No abstract available.

PMID:
27502988
13.

Should the United States Government Repeal Restrictions on Buprenorphine/Naloxone Treatment?

Blum K, Gold M, Clark HW, Dushaj K, Badgaiyan RD.

Subst Use Misuse. 2016 Oct 14;51(12):1674-1679. Epub 2016 Jul 27.

14.

Crystal Structure of a Complex of Surfactant Protein D (SP-D) and Haemophilus influenzae Lipopolysaccharide Reveals Shielding of Core Structures in SP-D-Resistant Strains.

Clark HW, Mackay RM, Deadman ME, Hood DW, Madsen J, Moxon ER, Townsend JP, Reid KBM, Ahmed A, Shaw AJ, Greenhough TJ, Shrive AK.

Infect Immun. 2016 Apr 22;84(5):1585-1592. doi: 10.1128/IAI.01239-15. Print 2016 May.

15.

Surfactant Protein-D Is Essential for Immunity to Helminth Infection.

Thawer S, Auret J, Schnoeller C, Chetty A, Smith K, Darby M, Roberts L, Mackay RM, Whitwell HJ, Timms JF, Madsen J, Selkirk ME, Brombacher F, Clark HW, Horsnell WG.

PLoS Pathog. 2016 Feb 22;12(2):e1005461. doi: 10.1371/journal.ppat.1005461. eCollection 2016 Feb.

16.

Airway Surfactant Protein D Deficiency in Adults With Severe Asthma.

Mackay RM, Grainge CL, Lau LC, Barber C, Clark HW, Howarth PH.

Chest. 2016 May;149(5):1165-72. doi: 10.1016/j.chest.2015.11.012. Epub 2016 Jan 13.

17.

Protective effects of surfactant protein D treatment in 1,3-β-glucan-modulated allergic inflammation.

Fakih D, Pilecki B, Schlosser A, Jepsen CS, Thomsen LK, Ormhøj M, Watson A, Madsen J, Clark HW, Barfod KK, Hansen S, Marcussen N, Jounblat R, Chamat S, Holmskov U, Sorensen GL.

Am J Physiol Lung Cell Mol Physiol. 2015 Dec 1;309(11):L1333-43. doi: 10.1152/ajplung.00090.2015. Epub 2015 Oct 2.

18.

Use of pharmacotherapies in the treatment of alcohol use disorders and opioid dependence in primary care.

Lee J, Kresina TF, Campopiano M, Lubran R, Clark HW.

Biomed Res Int. 2015;2015:137020. doi: 10.1155/2015/137020. Epub 2015 Jan 5. Review.

19.

Nanoparticles modulate surfactant protein A and D mediated protection against influenza A infection in vitro.

McKenzie Z, Kendall M, Mackay RM, Tetley TD, Morgan C, Griffiths M, Clark HW, Madsen J.

Philos Trans R Soc Lond B Biol Sci. 2015 Feb 5;370(1661):20140049. doi: 10.1098/rstb.2014.0049.

20.

Mechanism of neutrophil dysfunction: neutrophil serine proteases cleave and inactivate the C5a receptor.

van den Berg CW, Tambourgi DV, Clark HW, Hoong SJ, Spiller OB, McGreal EP.

J Immunol. 2014 Feb 15;192(4):1787-95. doi: 10.4049/jimmunol.1301920. Epub 2014 Jan 20.

21.

Functional heterogeneity of pulmonary surfactant protein-D in cystic fibrosis.

Kotecha S, Doull I, Davies P, McKenzie Z, Madsen J, Clark HW, McGreal EP.

Biochim Biophys Acta. 2013 Dec;1832(12):2391-400. doi: 10.1016/j.bbadis.2013.10.002. Epub 2013 Oct 9.

22.

Surfactant protein D (SP-D) deficiency is attenuated in humanised mice expressing the Met(11)Thr short nucleotide polymorphism of SP-D: implications for surfactant metabolism in the lung.

Knudsen L, Ochs K, Boxler L, Tornoe I, Lykke-Sorensen G, Mackay RM, Clark HW, Holmskov U, Ochs M, Madsen J.

J Anat. 2013 Dec;223(6):581-92. doi: 10.1111/joa.12120. Epub 2013 Sep 23.

23.

Surfactant Protein D modulates HIV infection of both T-cells and dendritic cells.

Madsen J, Gaiha GD, Palaniyar N, Dong T, Mitchell DA, Clark HW.

PLoS One. 2013;8(3):e59047. doi: 10.1371/journal.pone.0059047. Epub 2013 Mar 18.

24.

Increased prevalence of low oligomeric state surfactant protein D with restricted lectin activity in bronchoalveolar lavage fluid from preterm infants.

Kotecha S, Davies PL, Clark HW, McGreal EP.

Thorax. 2013 May;68(5):460-7. doi: 10.1136/thoraxjnl-2012-202729. Epub 2013 Feb 6.

PMID:
23390139
25.

Substance Abuse Treatment, HIV/AIDS, and the Continuum of Response for People Who Inject Drugs.

Kresina TF, Lubran R, Clark HW, Cheever LW.

Adv Prev Med. 2012;2012:541489. doi: 10.1155/2012/541489. Epub 2012 Nov 29.

26.

Meaningful use of electronic behavioral health data in primary health care.

Tai B, Boyle M, Ghitza U, Kaplan RM, Clark HW, Gersing K.

Sci Transl Med. 2012 Feb 1;4(119):119mr3. doi: 10.1126/scitranslmed.3003324.

PMID:
22301552
27.

Continuous glucose monitoring considerations for the development of a closed-loop artificial pancreas system.

Keenan DB, Grosman B, Clark HW, Roy A, Weinzimer SA, Shah RV, Mastrototaro JJ.

J Diabetes Sci Technol. 2011 Nov 1;5(6):1327-36.

28.

Electronic health records: essential tools in integrating substance abuse treatment with primary care.

Tai B, Wu LT, Clark HW.

Subst Abuse Rehabil. 2012 Feb 1;3:1-8. doi: 10.2147/SAR.S22575. eCollection 2012.

29.

A truly integrated treatment system must be both patient- and process-focused.

Clark HW.

Addiction. 2011 Dec;106(12):2068-9. doi: 10.1111/j.1360-0443.2011.03556.x. No abstract available.

PMID:
22049979
30.

Analysis of lung surfactant phosphatidylcholine metabolism in transgenic mice using stable isotopes.

Postle AD, Henderson NG, Koster G, Clark HW, Hunt AN.

Chem Phys Lipids. 2011 Sep;164(6):549-55. doi: 10.1016/j.chemphyslip.2011.04.004. Epub 2011 Apr 15.

PMID:
21515243
31.

Evaluation of full-length, cleaved and nitrosylated serum surfactant protein D as biomarkers for COPD.

Duvoix A, Miranda E, Perez J, Sorensen GL, Holmskov U, Trapnell BC, Madsen J, Clark HW, Edwards LD, Miller BE, Tal-Singer RM, Lomas DA.

COPD. 2011 Apr;8(2):79-95. doi: 10.3109/15412555.2011.558542.

PMID:
21495836
32.

Untapped therapeutic potential of surfactant proteins: is there a case for recombinant SP-D supplementation in neonatal lung disease?

Clark HW.

Neonatology. 2010 Jun;97(4):380-7. doi: 10.1159/000297770. Epub 2010 Jun 10. Review.

PMID:
20551708
33.

Recent advances in alveolar biology: evolution and function of alveolar proteins.

Orgeig S, Hiemstra PS, Veldhuizen EJ, Casals C, Clark HW, Haczku A, Knudsen L, Possmayer F.

Respir Physiol Neurobiol. 2010 Aug 31;173 Suppl:S43-54. doi: 10.1016/j.resp.2010.04.023. Epub 2010 Apr 28. Review.

34.

A case study in collaborating with Atlanta-based African-American churches: a promising means for reaching inner-city substance users with rapid HIV testing.

Whiters DL, Santibanez S, Dennison D, Clark HW.

J Evid Based Soc Work. 2010 Jan;7(1):103-14. doi: 10.1080/15433710903175981.

PMID:
20178028
35.

Structural characterisation of ligand-binding determinants in human lung surfactant protein D: influence of Asp325.

Shrive AK, Martin C, Burns I, Paterson JM, Martin JD, Townsend JP, Waters P, Clark HW, Kishore U, Reid KB, Greenhough TJ.

J Mol Biol. 2009 Dec 11;394(4):776-88. doi: 10.1016/j.jmb.2009.09.057. Epub 2009 Sep 30.

36.

Surfactant phospholipids, surfactant proteins, and inflammatory markers during acute lung injury in children.

Todd DA, Marsh MJ, George A, Henderson NG, Barr H, Sebastian S, Clark GT, Koster G, Clark HW, Postle AD.

Pediatr Crit Care Med. 2010 Jan;11(1):82-91. doi: 10.1097/PCC.0b013e3181ae5a4c.

PMID:
19550365
37.

Integration of viral hepatitis services into opioid treatment programs.

Kresina TF, Bruce RD, Lubran R, Clark HW.

J Opioid Manag. 2008 Nov-Dec;4(6):369-81.

PMID:
19192765
38.

Screening, brief interventions, referral to treatment (SBIRT) for illicit drug and alcohol use at multiple healthcare sites: comparison at intake and 6 months later.

Madras BK, Compton WM, Avula D, Stegbauer T, Stein JB, Clark HW.

Drug Alcohol Depend. 2009 Jan 1;99(1-3):280-95. doi: 10.1016/j.drugalcdep.2008.08.003. Epub 2008 Oct 16.

39.

Surfactant protein A binds to HIV and inhibits direct infection of CD4+ cells, but enhances dendritic cell-mediated viral transfer.

Gaiha GD, Dong T, Palaniyar N, Mitchell DA, Reid KB, Clark HW.

J Immunol. 2008 Jul 1;181(1):601-9.

40.

Hepatitis infection in the treatment of opioid dependence and abuse.

Kresina TF, Sylvestre D, Seeff L, Litwin AH, Hoffman K, Lubran R, Clark HW.

Subst Abuse. 2008 Apr 28;1:15-61. eCollection 2008. Review.

41.

Policy and practice implications of epidemiological surveys on co-occurring mental and substance use disorders.

Clark HW, Power AK, Le Fauve CE, Lopez EI.

J Subst Abuse Treat. 2008 Jan;34(1):3-13. Epub 2007 Jun 15.

PMID:
17574794
42.

Integrating hepatitis services into substance abuse treatment programs: new initiatives from SAMHSA.

Kresina TF, Hoffman K, Lubran R, Clark HW.

Public Health Rep. 2007;122 Suppl 2:96-8. No abstract available.

43.

Helicobacter infection in the surfactant protein D-deficient mouse.

Khamri W, Worku ML, Anderson AE, Walker MM, Hawgood S, Reid KB, Clark HW, Thursz MR.

Helicobacter. 2007 Apr;12(2):112-23.

PMID:
17309747
44.

A federal perspective on the abuse of prescription stimulants.

Clark HW, Bizzell AC.

Pediatr Ann. 2006 Aug;35(8):594-7. No abstract available.

PMID:
16986454
45.

Women, Co-occurring Disorders, and Violence Study: a case for trauma-informed care.

Clark HW, Power AK.

J Subst Abuse Treat. 2005 Mar;28(2):145-6. No abstract available.

PMID:
15780543
46.

A recombinant fragment of human SP-D reduces allergic responses in mice sensitized to house dust mite allergens.

Strong P, Townsend P, Mackay R, Reid KB, Clark HW.

Clin Exp Immunol. 2003 Nov;134(2):181-7.

47.

Office-based practice and opioid-use disorders.

Clark HW.

N Engl J Med. 2003 Sep 4;349(10):928-30. No abstract available.

PMID:
12954740
48.

New drug buprenorphine can treat patients addicted to heroin or prescription pain medications.

Clark HW.

W V Med J. 2003 Jan-Feb;99(1):42. No abstract available.

PMID:
12762216
49.

Moving from research to practice just in time: the treatment of cannabis use disorders comes of age.

Clark HW, MacNeill Horton A, Dennis M, Babor TF.

Addiction. 2002 Dec;97 Suppl 1:1-3.

PMID:
12460124
50.

Legal issues facing physicians: substance abuse in the workplace.

Clark HW, Johnson B.

Occup Med. 2002 Jan-Mar;17(1):119-35, v. Review.

PMID:
11726341

Supplemental Content

Loading ...
Support Center